TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06403813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents
Description: mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents
Description: mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents
Description: mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
Study: NCT04818957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)
Description: Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
Study: NCT06403813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents
Description: mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Tooklit
Description: The toolkit will have the same screening questions, with information, but without any decision support functions.
Study: NCT05800509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clips Intervention
Description: A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Structured Questionnaire Only
Description: A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
Study: NCT06249009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: CPAP and increasing flows of HFNC will be compared during a 30-minutes period each

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
Study: NCT06218199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torsemide
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: oral administration
Study: NCT06243614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules, 15mg/ capsule
Description: Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone tablets, 5mg/ tablet
Description: Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study: NCT06449846

Intervention type: DIAGNOSTIC_TEST
Intervention: circulating tumor cell DNA detection
Description: circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
Study: NCT05824455

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS109 combine with irinotecan
Description: JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
Study: NCT04345302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational treatment
Description: The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
Study: NCT05601908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Relaxation
Description: Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
Study: NCT05049343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-904
Description: SAGE-904 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-904
Description: SAGE-904 oral solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine intravenous (IV) infusion.
Study: NCT06243614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Study: NCT05049343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous (IV) infusion.
Study: NCT06243614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone tablets mimic, 0mg/ tablet
Description: Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buspirone tablets mimic, 0mg/ tablet
Description: Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Study: NCT05399966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monarda Didyma extract
Description: Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
Study: NCT05018494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental treatment
Description: This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common treatment
Description: This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
Study: NCT05759208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-101
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-101
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05886153

Intervention type: DEVICE
Group type: OTHER
Intervention: Vitaliti Continuous Vital Sign Monitor Model CVSM-1A
Description: Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
Study: NCT05042648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine patch
Description: Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
Study: NCT05840835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMX-110 combined with Tislelizumab
Description: Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Study: NCT04797377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous ovarian PRP injection
Description: The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
Study: NCT06252844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active control
Description: Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
Study: NCT04390542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning
Study: NCT05833035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583 mixed with [C-14] BI 1291583
Description: BI 1291583 mixed with \[C-14\] BI 1291583
Study: NCT05289089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychology Intervention
Description: Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
Study: NCT05005871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block after C-section surgery as postoperative pain management
Description: To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block after C-section surgery as postoperative pain management
Description: To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
Study: NCT04961138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transhepatic Arterial Chemotherapy And Embolization (TACE)
Description: Receiving TACE and lenvatinib before surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Removing tumor by surgery.
Study: NCT03019705

Intervention type: OTHER
Intervention: Observation
Study: NCT05480163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement records
Description: Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement records
Description: Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
Study: NCT05442567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Participants will not receive any intervention in the Observational Cohort.
Study: NCT06223178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thumb-tack needle
Description: Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham thumb-tack needle
Description: Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Basic gynecological treatment
Description: Gynecological health care guidance will be provided as patients needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic gynecological treatment
Description: Gynecological health care guidance will be provided as patients needed.
Study: NCT06017778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercise group
Description: 10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercise group
Description: 10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
Study: NCT06280612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pet therapy
Description: The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pet therapy
Description: The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.